<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2582">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04598581</url>
  </required_header>
  <id_info>
    <org_study_id>2020-02047qu20Papachristofilou</org_study_id>
    <nct_id>NCT04598581</nct_id>
  </id_info>
  <brief_title>Low Dose Radiation Therapy for Severe-Acute-Respiratory-Syndrome-Coronavirus-2 (SARS-CoV-2), COVID-19</brief_title>
  <acronym>COVID-RT-01</acronym>
  <official_title>Low Dose Radiation Therapy for Severe-Acute-Respiratory-Syndrome-Coronavirus-2 (SARS-CoV-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to analyse the efficacy of LD-RT for treatment of&#xD;
      Severe-Acute-Respiratory-Syndrome-Coronavirus-2 (SARS-CoV-2).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Management of patients with SARS-CoV-2 presents a great challenge in the ongoing pandemic.&#xD;
      The inflammatory reaction, evident in the later stages of the disease, is linked with high&#xD;
      mortality rates. Pharmaceutical interventions at this stage often do not achieve the desired&#xD;
      effects. Low Dose Radiation Therapy (LD-RT) has been utilized for treatment of inflammatory&#xD;
      conditions because of its immunomodulatory effects. Thus, LD-RT may be an option in&#xD;
      SARS-CoV-2 based on pre-clinical models and early clinical data. This study is to analyse the&#xD;
      efficacy of LD-RT for treatment of Severe-Acute-Respiratory-Syndrome-Coronavirus-2&#xD;
      (SARS-CoV-2).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 2, 2020</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Information on group allocation will not be disclosed to either the patient or the ICU-staff.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Ventilator free days (VFD)</measure>
    <time_frame>at day 15 after LD-RT</time_frame>
    <description>Ventilator free days (VFD)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in pulmonary function, measured as relative change (%) from baseline in oxygenation index (PaO2 / FiO2)</measure>
    <time_frame>at day 5, 10, 15, 28 after LD-RT</time_frame>
    <description>Change in pulmonary function, measured as relative change (%) from baseline in oxygenation index (PaO2 / FiO2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall mortality</measure>
    <time_frame>at day 15 and 28 after LD-RT</time_frame>
    <description>Overall mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in levels of ferritin (ng/ml)</measure>
    <time_frame>up to day 15 after LD-RT</time_frame>
    <description>Change in levels of ferritin (ng/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in levels of c-reactive protein (mg/l)</measure>
    <time_frame>up to day 15 after LD-RT</time_frame>
    <description>Change in levels of c-reactive protein (mg/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in levels of white blood cell counts (number of white blood cells per volume of blood)</measure>
    <time_frame>up to day 15 after LD-RT</time_frame>
    <description>Change in levels of white blood cell counts (number of white blood cells per volume of blood)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Severe-Acute-Respiratory-Syndrome-Coronavirus-2 (SARS-CoV-2)</condition>
  <arm_group>
    <arm_group_label>Low Dose Radiation Therapy (LD-RT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham irradiation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Low Dose Radiation Therapy (LD-RT)</intervention_name>
    <description>Low Dose Radiation Therapy (LD-RT) of both lungs with 1 Gray</description>
    <arm_group_label>Low Dose Radiation Therapy (LD-RT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham irradiation</intervention_name>
    <description>Sham irradiation</description>
    <arm_group_label>Sham irradiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age of male patients &gt;40 years&#xD;
&#xD;
          -  Age of female patients &gt;50 years&#xD;
&#xD;
          -  Patients with SARS-CoV-2 requiring mechanical ventilation&#xD;
&#xD;
          -  Informed consent obtained by the legal representative of the patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandros Papachristofilou, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Radiooncology, University Hospital Basel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Radiooncology, University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 20, 2020</study_first_submitted>
  <study_first_submitted_qc>October 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>January 4, 2021</last_update_submitted>
  <last_update_submitted_qc>January 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Low dose radiation therapy (LD-RT)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

